All findings are directional signals derived from consumer conversation data and do not represent verified sales, revenue, or market share figures
References Muhammad Khan, MD, MPH
A recent Phase 2 randomised placebo-controlled trial tested efinopegdutide in people with obesity over a 26-week period, where participants were randomly assigned weekly treatment with either placebo, 5 mg, 7.4 mg, 10 mg efinopegdutide, or 3 mg liraglutide daily
Researchers pointed to factors such as cost, accessibility, and medication side effects as potential contributors to these trends
Whether you're preparing for a big event or just want to improve your day-to-day skin health, incorporating these patches into your regimen can make a significant difference